Literature DB >> 9075278

Production of interferon-gamma in families with multiple occurrence of schizophrenia.

V Arolt1, C Weitzsch, I Wilke, A Nolte, M Pinnow, M Rothermundt, H Kirchner.   

Abstract

Dysfunction of T-cell mediated immunity, which is indicated by deficient production of interleukin-2 (IL-2) and elevated levels of the soluble interleukin-2 receptor (sIL-2R), has been consistently demonstrated in schizophrenia. Recent studies on interferon-gamma (IFN-gamma), a cytokine which is also produced by T-helper cells, have indicated a lowered production in acute schizophrenia. It is not known whether this deficit is restricted to cases of acute schizophrenia or whether it is also present in residual schizophrenia and in first degree relatives, and therefore might be associated with genetic liability to the disease. We investigated 27 individuals (schizophrenics and first degree relatives) of 6 families with multiple occurrence of schizophrenia and 27 age- and sex-matched healthy controls. The production of IFN-gamma was lowered only in the acutely ill schizophrenic individuals, when compared to both controls and first degree relatives. In the context of current knowledge, this result indicates that the production of IFN-gamma can be discussed as a marker of acute exacerbation of schizophrenia, but it is not likely to represent a phenotypic marker of a genetic trait associated with the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9075278     DOI: 10.1016/s0165-1781(96)03023-5

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Markers of inflammation in schizophrenia: association vs. causation.

Authors:  Peter Manu; Christoph U Correll; Martien Wampers; Alex J Mitchell; Michel Probst; Davy Vancampfort; Marc De Hert
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

2.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Authors:  Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-17       Impact factor: 4.105

3.  Association study of interferon gamma (IFN-γ) +874T/A gene polymorphism in patients with paranoid schizophrenia.

Authors:  Monika Paul-Samojedny; Aleksander Owczarek; Renata Suchanek; Malgorzata Kowalczyk; Anna Fila-Danilow; Paulina Borkowska; Krzysztof Kucia; Jan Kowalski
Journal:  J Mol Neurosci       Date:  2010-09-04       Impact factor: 3.444

4.  Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls.

Authors:  Marcella Reale; Antonia Patruno; Maria A De Lutiis; Mirko Pesce; Mario Felaco; Massimo Di Giannantonio; Marta Di Nicola; Alfredo Grilli
Journal:  BMC Neurosci       Date:  2011-01-25       Impact factor: 3.288

5.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

Review 6.  [Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness].

Authors:  A Schuld; D Hinze-Selch; Th Pollmächer
Journal:  Nervenarzt       Date:  2004-03       Impact factor: 1.214

7.  Pro-inflammatory cytokines and their epistatic interactions in genetic susceptibility to schizophrenia.

Authors:  Lekshmy Srinivas; Neetha N Vellichirammal; Ann Mary Alex; Chandrasekharan Nair; Indu V Nair; Moinak Banerjee
Journal:  J Neuroinflammation       Date:  2016-05-13       Impact factor: 8.322

8.  The Microbiome: A New Target for Research and Treatment of Schizophrenia and its Resistant Presentations? A Systematic Literature Search and Review.

Authors:  Alessandro Cuomo; Giuseppe Maina; Gianluca Rosso; Bruno Beccarini Crescenzi; Simone Bolognesi; Angela Di Muro; Nicola Giordano; Arianna Goracci; Stephen M Neal; Maria Nitti; Fulvio Pieraccini; Andrea Fagiolini
Journal:  Front Pharmacol       Date:  2018-10-15       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.